Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud Rent for 48h to view Buy Cloud Access for unlimited viewing via different devices Synchronizing in the ReadCube Cloud Printing and saving restrictions apply Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 17, 2021
Accepted: November 03, 2021
Published online: November 08, 2021
Issue release date: Published online first

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 2

ISSN: 0001-5652 (Print)
eISSN: 1423-0062 (Online)

For additional information: https://www.karger.com/HHE

Abstract

Introduction: Liver disease accounts for approximately 2 million deaths per year worldwide. The majority of liver diseases are due to complications of cirrhosis, viral hepatitis, and hepatocellular carcinoma. Increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may indicate liver disease. Moreover, there are additional noninvasive liver fibrosis indices that help to estimate liver damage, including AST-to-ALT ratio, AST-to-platelet ratio index (APRI), fibrosis-4 (FIB-4) score, and nonalcoholic fatty liver disease (NAFLD) fibrosis score. The aims of the present study were to (1) perform an association analysis of the patatin-like phospholipase domain containing 3 (PNPLA3) I148M (rs738409) variant with ALT, AST, and various liver fibrosis indices, and (2) determine whether there are gender-related differences in these associations. Methods: We obtained demographic, anthropometric, and metabolic phenotypes from Latino adult participants (n = 503, 64% female, 36.4 ± 0.5 years) from the Arizona Insulin Resistance (AIR) registry. SNP genotyping of I148M was performed using the TaqMan allelic discrimination assay. We used linear regression for the association analyses of the genotypes with ALT, AST, and the various liver fibrosis indices. We included genotype, age, body mass index, and alcohol status in the linear regression model. Results: The variant I148M was in Hardy-Weinberg equilibrium, with genotype distribution: non-risk CC 118, heterozygous CG 246, and risk GG 139. The G allele was significantly associated with increased ALT and AST levels (p = 7.8 × 10–7 and p = 9.7 × 10–6, respectively). Moreover, we showed that the G allele was significantly associated with higher APRI (p = 3.7 × 10–7) and FIB-4 score (p = 4.1 × 10–3). When we analyzed the data by gender, we observed similar significant trends for ALT, AST, and APRI (all, p < 0.01). In females, the G allele was significantly associated with increased FIB-4 score (p = 6.9 × 10–3), which was not observed in the males (p > 0.05). There was no association of the I148M variant with AST/ALT ratio nor NAFLD risk score, whether analyzed in all adults or by gender. Discussion/Conclusion: Our findings provide additional evidence of an association of PNPLA3 I148M with several liver disease biomarkers in male and female Latinos residing in the Southwest of the United States.

© 2021 S. Karger AG, Basel

References Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019 Jan;70(1):151–71. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008 Mar;371(9615):838–51. Smith A, Baumgartner K, Bositis C. Cirrhosis: diagnosis and Management. Am Fam Physician. 2019 Dec;100(12):759–70. Wong MC, Huang J. The growing burden of liver cirrhosis: implications for preventive measures. Hepatol Int. 2018 May;12(3):201–3. Collaborators GB; GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245–66. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999 Apr;94(4):1018–22. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001 Nov;96(11):3142–6. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006 Jun;73(11):1961–8. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518–26. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al.; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317–25. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007 Apr;45(4):846–54. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020 Jul;73(1):202–9. Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020 Dec;40(12):3018–30. Casler K, Chaney A. Cirrhosis: an evidence-based treatment approach. Nurse Pract. 2020 Aug;45(8):16–26. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008 Dec;40(12):1461–5. Namjou B, Lingren T, Huang Y, Parameswaran S, Cobb BL, Stanaway IB, et al.; eMERGE Network. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med. 2019 Jul;17(1):135. Young KA, Palmer ND, Fingerlin TE, Langefeld CD, Norris JM, Wang N, et al. Genome-Wide Association Study Identifies Loci for Liver Enzyme Concentrations in Mexican Americans: the GUARDIAN Consortium. Obesity (Silver Spring). 2019 Aug;27(8):1331–7. Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. J Hepatol. 2016 Aug;65(2):399–412. Wagenknecht LE, Palmer ND, Bowden DW, Rotter JI, Norris JM, Ziegler J, et al. Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int. 2011 Mar;31(3):412–6. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, et al.; Japan Study Group of Nonalcoholic Fatty Liver Disease. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One. 2012;7(6):e38322. Li Q, Qu HQ, Rentfro AR, Grove ML, Mirza S, Lu Y, et al. PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population. Clin Invest Med. 2012 Aug;35(4):E237–45. Martínez LA, Larrieta E, Kershenobich D, Torre A. The Expression of PNPLA3 Polymorphism could be the Key for Severe Liver Disease in NAFLD in Hispanic Population. Ann Hepatol. 2017 Nov-Dec;16(6):909–15. Chinchilla-López P, Ramírez-Pérez O, Cruz-Ramón V, Canizales-Quinteros S, Domínguez-López A, Ponciano-Rodríguez G, et al. More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3. Ann Hepatol. 2018 Mar;17(2):250–5. Kolla BP, Schneekloth TD, Biernacka J, Shah V, Lazaridis KN, Geske J, et al. PNPLA3 Association with Alcoholic Liver Disease in a Cohort of Heavy Drinkers. Alcohol Alcohol. 2018 Jul;53(4):357–60. Meffert PJ, Repp KD, Völzke H, Weiss FU, Homuth G, Kühn JP, et al. The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort. J Hepatol. 2018 Apr;68(4):858–60. Tepper CG, Dang JH, Stewart SL, Fang DM, Wong KA, Liu SY, et al. High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer. 2018 Apr;124 Suppl 7:1583–9. Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Jun;1864(6):900–6. McHenry S, Davidson NO. Missense Mutant Patatin-Like Phospholipase Domain Containing 3 Alters Lipid Droplet Turnover in Partnership With CGI-58. Hepatology. 2019 Jun;69(6):2323–5. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009 Jun;52(6):1056–60. He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010 Feb;285(9):6706–15. Shaibi GQ, Coletta DK, Vital V, Mandarino LJ. The design and conduct of a community-based registry and biorepository: a focus on cardiometabolic health in Latinos. Clin Transl Sci. 2013 Dec;6(6):429–34. DeMenna J, Puppala S, Chittoor G, Schneider J, Kim JY, Shaibi GQ, et al. Association of common genetic variants with diabetes and metabolic syndrome related traits in the Arizona Insulin Resistance registry: a focus on Mexican American families in the Southwest. Hum Hered. 2014;78(1):47–58. Article / Publication Details

First-Page Preview

Received: May 17, 2021
Accepted: November 03, 2021
Published online: November 08, 2021
Issue release date: Published online first

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 2

ISSN: 0001-5652 (Print)
eISSN: 1423-0062 (Online)

For additional information: https://www.karger.com/HHE